Just overall a great experience
Cardiovasc Res 36:276281 Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M et al (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2
Research models often examine NNMT inhibition in the context of substrate recycling, signaling efficiency, and cellular stress response mechanisms
It does not look like a rash or redness
They will propose the best course of action and ensure your health and safety aren't jeopardized during this treatment